Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials

Seminars in Oncology

Volumn 44, Issue 1, 2017, Pages 3-7

  Kazandjian, Dickran ^a,b   Keegan, Patricia ^a   Suzman, Daniel L ^a   Pazdur, Richard ^a   Blumenthal, Gideon M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Non small cell lung carcinoma; PD 1 inhibitor; Treatment beyond progression

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METASTASIS; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85014331014     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2017.01.001     Document Type: Article

References (25)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
2. [2] Herbst, R.S., Gandara, D.R., Hirsch, F.R., et al. Lung Master Protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 21:7 (2015), 1514–1524.
3. [3] Shepherd, F.A., Dancey, J., Ramlau, R., et al. prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:10 (2000), 2095–2103.
4. [4] Hanna, N., Shepherd, F.A., Fossella, F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:9 (2004), 1589–1597.
5. [5] Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 353:2 (2005), 123–132.
6. [6] Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348:6230 (2015), 124–128.
7. [7] Kazandjian, D., Khozin, S., Blumenthal, G., et al. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: a report from the US Food and Drug Administration. JAMA Oncol, 2015, 1–5.
8. [8] Kazandjian, D., Suzman, D.L., Blumenthal, G., et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21:5 (2016), 634–642.
9. [9] Sul, J., Blumenthal, G.M., Jiang, X., He, K., Keegan, P., Pazdur, R., FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21:5 (2016), 643–650.
10. [10] Davies, M., New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 6 (2014), 63–75.
11. [11] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:2 (2009), 228–247.
12. [12] Wolchok, J.D., Hoos, A., OʼDay, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Am Assoc Cancer Res 15:23 (2009), 7412–7420.
13. [13] Hodi, F.S., Hwu, W.-J., Kefford, R., et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:13 (2016), 1510–1517.
14. [14] Oxnard, G.R., Morris, M.J., Hodi, F.S., et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. JNCI 104:20 (2012), 1534–1541.
15. [15] Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
16. [16] Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
17. [17] Langer CJ. Emerging Immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2015;38(4):422-30.
18. [18] Ansell, S.M., Lesokhin, A.M., Borrello, I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkinʼs lymphoma. N Engl J Med 372:4 (2015), 311–319.
19. [19] Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
20. [20] Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
21. [21] Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
22. [22] George, S., Motzer, R.J., Hammers, H.J., et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 33:31 (2016), 1179–1186.
23. [23] Chiou, V.L., Burotto, M., pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:31 (2015), 3541–3543.
24. [24] Weinstock, C., Maher, V.E., Zhang, L., et al. FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus. J Clin Oncol, 34(suppl), 2016, 4508.
25. [25] Escudier, B.J., Motzer, R.J., Sharma, P., et al. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. J Clin Oncol, 34(suppl), 2016, 4509.